Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations
Clinical Pharmacology & Therapeutics · 2025-07 · 118 (1) · 146-155
DOI: 10.1002/cpt.3652 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025-04. Verfasst von Alice S Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Drugs, Investigational. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Genentech Inc.
Abstract (Originalsprache)
A common issue in clinical drug development involves drug–drug interactions (DDI) that may lead to altered drug exposure and subsequent altered safety and efficacy of an investigational drug or concomitant medications (conmeds) in the target patient population. The drug development pipeline therefore involves DDI risk assessment of the investigational drug based on in vitro studies, in silico modeling, and clinical trials. Real‐world data (RWD), particularly claims databases with reliable information on pharmacy dispensing, provide an opportunity to understand conmeds usage in the target indication in a real‐world setting as one approach to assess potential DDI risk. We describe two cases of characterizing DDI‐related conmeds usage with a large closed US‐based claims database, IQVIA PharMetrics® Plus, and identified potential DDI risk for multiple sclerosis and hormone receptor‐positive breast cancer. For example, prevalent and chronic use of statins (atorvastatin and simvastatin), which are CYP3A4 substrates, were identified among both disease cases. Further examples, limitations, and future directions are also discussed. These insights can therefore help augment decision‐making during clinical drug research and development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
- Product Development Data Science and Real World Data Science, Genentech, Inc., South San Francisco, California, USA.
- Clinical Pharmacology, Genentech/Roche, Inc., Lyon, France.
ORCID-Profile: Alice S Tang, Logan Brooks, Pascal Chanu, Amita Joshi, Bianca Vora, Rui Zhu
Förderung
- Genentech Inc
Zitieren
APA
Tang, A. S., Brooks, L., Boudreau, D. M., Chanu, P., Joshi, A., Vora, B., & Zhu, R. (2025). Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations. Clinical Pharmacology & Therapeutics, 118(1), 146-155. https://doi.org/10.1002/cpt.3652
Vancouver
Tang AS, Brooks L, Boudreau DM, Chanu P, Joshi A, Vora B, et al. Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations. Clinical Pharmacology & Therapeutics. 2025;118(1):146-155. doi:10.1002/cpt.3652
BibTeX
@article{Tang2025,
author = {Tang, Alice S and Brooks, Logan and Boudreau, Denise M and Chanu, Pascal and Joshi, Amita and Vora, Bianca and Zhu, Rui},
title = {Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {118},
number = {1},
pages = {146--155},
doi = {10.1002/cpt.3652}
}
EUVIMED